[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"occupational-exposure-to-chemicals\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:occupational-exposure-to-chemicals":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":37,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100639368","phase-2-use-of-bile-acid-binding-resins-to-decrease-pfas-levels-via-colesevalem-in-veterans-study-100639368",false,"NCT07592858","Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study","Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study","PAVERS","Inclusion:\n\n* Male or female Veterans aged 25- 65 who have serum PFAS \\>20 ng\u002Fml exceeding National Academy of Science guidance.\n* Written informed consent will be obtained.\n* Outpatient.\n* Agreeable to participate in sharable data and biorepository.\n\nExclusion:\n\n* Under the age of 25 years\n* Unable or unwilling to sign the informed consent statement and HIPAA Authorization form\n* Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period.\n* Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction\n* Be receiving any investigational drug other than Colesevelam or participating in any other investigational study.\n* Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator.\n* Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results.\n* Those with significant cardiovascular disease including treatment with inotropes.\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.",true,"ALL","25 Years","65 Years",{"count":22,"type":23},50,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the National Academies Science criteria (PFASsix \\> 20 ng\u002Fml) using a double blind-placebo controlled study. Based on PFAS prevalence in serum samples, we anticipate recruiting up to n=500 Veterans to meet the goal of n=50 study participants to receive intervention or placebo. The primary outcome will be initial and final PFAS content in serum (total and 7 individual PFAS). The secondary outcome will be initial and final serum biomarkers related to lipid metabolism. As an exploratory aspect to the proposal, we will also measure fecal PFAS, bile acids, and microbial diversity to examine associations between PFAS content and bile acid levels and microbiome. Fecal PFAS, bile acid content, and microbiome may also be measured.",[29,30,31,32,33,34,35,36],"PFAS","Environmental Exposures","Occupational Exposure to Chemicals","Military Exposure","Burn Pit Exposure","Forever Chemicals","Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia","Hyperlipidemia (E.G., Hypercholesterolemia)",[29,38,39,40],"Military exposure","Forever chemicals","Colesevelam","NOT_YET_RECRUITING","2026-05-11",{"date":44,"type":45},"2026-05-18","ACTUAL",{"date":47,"type":23},"2026-07-01",{"date":49,"type":23},"2029-09-29",{"name":51,"class":52},"University of Rhode Island","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":62,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100610350","phase-1-examining-a-novel-gastrointestinal-intervention-to-negate-environmental-toxicants-engine-100610350","NCT07226440","Examining a Novel Gastrointestinal Intervention to Negate Environmental Toxicants (ENGINE)","Assessing the Impact of a Bile Acid Sequestrant on Serum PFAS Levels in Highly Exposed Individuals","ENGINE","Inclusion Criteria:\n\n* Male firefighter, active or retired\n* California resident\n* Age 18 or older\n* English-speaking\n* Access to a reliable internet connection\n* Willing to attend 3 in-person study visits in the San Francisco Bay Area over about 6.5 months\n* Willing to receive weekly text message reminders to complete online surveys\n* Willing to complete a mail-based, at-home finger-prick blood test\n* Willing to take 3 tablets (each tablet about the size of a multivitamin) orally twice daily for a total of 6 months\n* Evaluated by study team to have an elevated risk of PFAS exposure (e.g., duration of firefighting service, prior NASEM-7 result greater than or equal to 10 ng\u002FmL)\n\nExclusion Criteria:\n\n* Gastroparesis or other severe gastrointestinal motility disorders\n* Bowel obstruction\n* History of major gastrointestinal tract surgery\n* Dysphagia or difficulty swallowing (due to tablet size)\n* History of hypertriglyceridemia (triglycerides exceeding 500 mg\u002FdL)\n* History of hypertriglyceridemia-induced pancreatitis\n* Type 1 or 2 diabetes\n* History of fat-soluble vitamin deficiencies, i.e., vitamins A, D, E, or K\n* Phenylketonuria\n* History of known bleeding\u002Fclotting disorders\n* Medications or treatments that may impact the excretion of PFAS, such as activated charcoal, other bile acid sequestrants, chelation therapies, etc.\n* Unalterable plans to donate blood or plasma during the study participation period","MALE","18 Years",{"count":22,"type":23},[66,26],"PHASE1","This randomized, placebo-controlled crossover trial will test the feasibility and acceptability of using colesevelam in male firefighters with high per- and polyfluoroalkyl substances (PFAS) exposure. This trial will also explore whether colesevelam lowers blood PFAS levels and urine environmental toxicant and mold mycotoxin levels.",[69,70,31],"Toxicant Exposure","Firefighter",[72,29,73,74,75,40],"Per- and polyfluoroalkyl substances","Firefighters","Occupational exposure","Bile acid sequestrants","RECRUITING","2026-04-22",{"date":79,"type":45},"2026-04-24",{"date":81,"type":45},"2026-03-01",{"date":83,"type":23},"2028-12",{"name":85,"class":52},"University of California, San Francisco",1]